

Contact:
PRISM BioLab Co., Ltd.
info@prismbiolab.com

26-1, Muraoka-Higashi 2-
chome, Fujisawa,
Kanagawa 251-8555
<https://prismbiolab.com>



PRISM
BioLab

PRESS RELEASE

Notice of Expiration of the Research and License Agreement with Boehringer Ingelheim International GmbH

TOKYO, Japan, May 15, 2026: -- PRISM BioLab, Co., Ltd. ("PRISM") hereby announces that the research and license agreement (the "Agreement") between PRISM and Boehringer Ingelheim International GmbH ("BI") will expire upon the completion of its contractual term, as outlined below.

PRISM and BI entered into the Agreement on May 18, 2020. Under the Agreement, PRISM provided its proprietary small-molecule library compounds for the purpose of screening for hit compounds against BI's drug discovery targets, and has received payments from BI for the use of such compounds. Following discussions between the parties regarding the future handling of the Agreement, the parties confirmed that the Agreement will expire on May 16, 2026 in accordance with its predetermined term.

No additional financial obligations will arise in connection with the expiration of the Agreement, and the expiration is not expected to have any material impact on PRISM's financial results for the fiscal year.

Sincerely,
PRISM BioLab Co., Ltd.